Behavioral health interventions traditionally use a simple dichotomous outcome criterion: 'success' or 'failure'. In reality, though, behavior change is a complex process in which several steps towards success are taken. There has been little consideration, however, about whether future behavior change should be incorporated in cost-effectiveness analyses (CEAs). The aim of the present review is to identify and evaluate the usage of cognitive, intermediate outcomes PriceSpective, London, UK OBJECTIVES: To develop a quantitative model that can determine the effect of segmentation and positioning on revenue generation based on different variables, health economic considerations and pricing scenarios, creating a tool which is easy to use for the first evaluation of options. METHODS: Literature review and interviews with industry experts were conducted followed by the development of qualitative framework, logic and the subsequently a quantitative model. The model was tested and validated using real life examples. RESULTS: A qualitative model was developed which presents an iterative strategy to align stakeholders' interest with different scenarios of segmentation. From a given asset base of active ingredients, the pharmaceutical company defines therapeutic areas for a component and determines segments within them, evaluating both attractiveness and specific propositions for patients, payers and prescribers in comprehensive scenarios. For the payer's perspective in particular, health economic benefits of the proposed segmentation approach must be contemplated. Following this analysis, objectives and strategies for the chosen segments are developed and a holistic value proposition can be delivered to the market. Ideally, the process should be initiated early during development in order to design clinical trials according to the segmentation strategy. The process should also be monitored throughout the marketing and sales process in order to make improvements, and to react to changes in health care policies or the competitive landscape. Following the qualitative analysis, a quantitative model was developed in Excel that captures the effect of multiple variables such as age, gender, disease severity, co-morbidities, insurance type and multiple price points on revenue generation, positioning and pricing of pharmaceuticals. The model was tested and validated using the example of bipolar disorder (BPD) in women with childbearing potential. A new product with lower teratogenic risks was evaluated along different segmentation scenarios in order to determine improved overall cost-effectiveness when compared to conventional treatments. CONCLUSIONS: Segmentation is an important tool that could lead to better revenue generation from the company's perspective and is accepted positively by payers due to optimized budget impact with better health outcomes. Bristol-Myers Squibb, Princeton, NJ, USA BACKGROUND: In model-based health economic evaluations, to achieve a given level of precision surrounding modelled outputs there is a trade-off between treatment effect estimates and the computational time associated with the programming format used to 'code' the model. OBJECTIVES: To explore the relationship between modelled effect size, statistical precision and the computational time associated with two commonly used programming frameworks. METHODS: A published and validated cost-utility discrete event simulation (DES) diabetes model (Cardiff model) was programmed in MS Excel with Visual Basic (VB), and more recently reprogrammed in C as with other models in this area, to illustrate the efficiency gains in terms of computational speed achieved under different programming frameworks. A treatment effect of 0.4% HbA1c improvement was applied to a mean cohort profile of 10,000 patients; precision in the predicted number of clinical events was used to assess relative efficiency of VB and C. RESULTS: In the C programmed model in order to show a significant difference at the 95% level in the predicted number of events in the control and treatment arms required 50 iterations of the model using mean values. This equated to a model run time of 1 minute. The equivalent number of iterations in VB took 133 minutes to demonstrate a significant difference in the predicted number of events. Typically, one-way sensitivity analysis using this model to explore 40 scenarios would equate to a run time of 40 minutes in C and 5,320 minutes (88.7 hours) in VB. CONCLUSIONS: Programming format can impact the computational time associated with running the model with subsequent practical implications for the usability of the model. We conclude that with reasonably complex models, Abstracts A565
PriceSpective, London, UK OBJECTIVES: To develop a quantitative model that can determine the effect of segmentation and positioning on revenue generation based on different variables, health economic considerations and pricing scenarios, creating a tool which is easy to use for the first evaluation of options. METHODS: Literature review and interviews with industry experts were conducted followed by the development of qualitative framework, logic and the subsequently a quantitative model. The model was tested and validated using real life examples. RESULTS: A qualitative model was developed which presents an iterative strategy to align stakeholders' interest with different scenarios of segmentation. From a given asset base of active ingredients, the pharmaceutical company defines therapeutic areas for a component and determines segments within them, evaluating both attractiveness and specific propositions for patients, payers and prescribers in comprehensive scenarios. For the payer's perspective in particular, health economic benefits of the proposed segmentation approach must be contemplated. Following this analysis, objectives and strategies for the chosen segments are developed and a holistic value proposition can be delivered to the market. Ideally, the process should be initiated early during development in order to design clinical trials according to the segmentation strategy. The process should also be monitored throughout the marketing and sales process in order to make improvements, and to react to changes in health care policies or the competitive landscape. Following the qualitative analysis, a quantitative model was developed in Excel that captures the effect of multiple variables such as age, gender, disease severity, co-morbidities, insurance type and multiple price points on revenue generation, positioning and pricing of pharmaceuticals. The model was tested and validated using the example of bipolar disorder (BPD) in women with childbearing potential. A new product with lower teratogenic risks was evaluated along different segmentation scenarios in order to determine improved overall cost-effectiveness when compared to conventional treatments. CONCLUSIONS: Segmentation is an important tool that could lead to better revenue generation from the company's perspective and is accepted positively by payers due to optimized budget impact with better health outcomes. Bristol-Myers Squibb, Princeton, NJ, USA BACKGROUND: In model-based health economic evaluations, to achieve a given level of precision surrounding modelled outputs there is a trade-off between treatment effect estimates and the computational time associated with the programming format used to 'code' the model. OBJECTIVES: To explore the relationship between modelled effect size, statistical precision and the computational time associated with two commonly used programming frameworks. METHODS: A published and validated cost-utility discrete event simulation (DES) diabetes model (Cardiff model) was programmed in MS Excel with Visual Basic (VB), and more recently reprogrammed in C as with other models in this area, to illustrate the efficiency gains in terms of computational speed achieved under different programming frameworks. A treatment effect of 0.4% HbA1c improvement was applied to a mean cohort profile of 10,000 patients; precision in the predicted number of clinical events was used to assess relative efficiency of VB and C. RESULTS: In the C programmed model in order to show a significant difference at the 95% level in the predicted number of events in the control and treatment arms required 50 iterations of the model using mean values. This equated to a model run time of 1 minute. The equivalent number of iterations in VB took 133 minutes to demonstrate a significant difference in the predicted number of events. Typically, one-way sensitivity analysis using this model to explore 40 scenarios would equate to a run time of 40 minutes in C and 5,320 minutes (88.7 hours) in VB. CONCLUSIONS: Programming format can impact the computational time associated with running the model with subsequent practical implications for the usability of the model. We conclude that with reasonably complex models, Abstracts A565
PMC21 ASSESSING THE RELATIONSHIP BETWEEN COMPUTATIONAL SPEED AND PRECISION: A CASE STUDY USING A DISCRETE EVENT SIMULATION MODEL IN DIABETES CARE

Gordon
